AN2 Therapeutics, Inc. (ANTX) stock
ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.55+0.11 (+2.48%)
Close on Nov 13, 2026Market cap $171.70MP/E –Yield –
AN2 Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
AN2 Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $25.37M, up 8.9% year over year. For fiscal 2025 it was $24.77M, down 38.8% from the year before. The highest annual figure on record is $54.87M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.77M | -38.8% |
| FY2024 | Dec 31, 2024 | $40.49M | -26.2% |
| FY2023 | Dec 31, 2023 | $54.87M | +92.5% |
| FY2022 | Dec 31, 2022 | $28.51M | +76.5% |
| FY2021 | Dec 31, 2021 | $16.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.72M | -18.2% |
| Q2 FY2026 | Jun 30, 2026 | $6.02M | +88.1% |
| Q1 FY2026 | Mar 31, 2026 | $6.74M | -12.3% |
| Q4 FY2025 | Dec 31, 2025 | $6.88M | +27.5% |
| Q3 FY2025 | Sep 30, 2025 | $7.00M | -15.5% |
| Q2 FY2025 | Jun 30, 2025 | $3.20M | -73.7% |
| Q1 FY2025 | Mar 31, 2025 | $7.69M | -47.5% |
| Q4 FY2024 | Dec 31, 2024 | $5.40M | -63.8% |
| Q3 FY2024 | Sep 30, 2024 | $8.29M | -42.6% |
| Q2 FY2024 | Jun 30, 2024 | $12.15M | -10.3% |
| Q1 FY2024 | Mar 31, 2024 | $14.66M | +22.3% |
| Q4 FY2023 | Dec 31, 2023 | $14.92M | +70.5% |
| Q3 FY2023 | Sep 30, 2023 | $14.43M | +94.3% |
| Q2 FY2023 | Jun 30, 2023 | $13.54M | +102.1% |
| Q1 FY2023 | Mar 31, 2023 | $11.99M | +112.8% |
| Q4 FY2022 | Dec 31, 2022 | $8.75M | +64.8% |
| Q3 FY2022 | Sep 30, 2022 | $7.43M | +39.0% |
| Q2 FY2022 | Jun 30, 2022 | $6.70M | +74.0% |
| Q1 FY2022 | Mar 31, 2022 | $5.63M | +241.6% |
| Q4 FY2021 | Dec 31, 2021 | $5.31M | – |
| Q3 FY2021 | Sep 30, 2021 | $5.35M | – |
| Q2 FY2021 | Jun 30, 2021 | $3.85M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.65M | – |
See a number that looks wrong?